How big is Pulmatrix, Inc.?

As of Jun 18, Pulmatrix, Inc. has a market capitalization of 29.80 million and reported net sales of 1.92 million with a net profit of -12.20 million over the latest four quarters. Shareholder's funds are 8.95 million and total assets are 9.94 million as of Dec 24.

As of Jun 18, Pulmatrix, Inc. has a market capitalization of 29.80 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 1.92 million, while the sum of Net Profit for the same period is -12.20 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 8.95 million and Total Assets at 9.94 million.

What does Pulmatrix, Inc. do?

Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies for serious respiratory diseases, with a market cap of $29.80 million and a recent net profit of -$2 million. The company operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap entity.

Overview: <BR>Pulmatrix, Inc. is a clinical stage biopharmaceutical company focused on developing inhaled therapies for serious respiratory diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>- Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>- Market cap: USD 29.80 Million (Micro Cap) <BR><BR>Key Metrics: <BR>- P/E: NA (Loss Making) <BR>- Industry P/E: NA <BR>- Dividend Yield: 0.00% <BR>- Debt Equity: -1.08 <BR>- Return on Equity: -170.58% <BR>- Price to Book: 4.17 <BR><BR>Contact Details: <BR>- Address: 99 Hayden Ave Ste 390, LEXINGTON MA: 02421-7966 <BR>- Tel: 1 781 3572333 <BR>- Website: http://www.pulmatrix.com/

Should I buy, sell or hold Pulmatrix, Inc.?

Who are in the management team of Pulmatrix, Inc.?

As of March 2022, the management team of Pulmatrix, Inc. includes Mr. Michael Higgins (Independent Chairman), Mr. Teofilo Raad (President and CEO), and several directors: Mr. Todd Bazemore, Dr. Christopher Cabell, Dr. Rick Batycky, Mr. Mark Iwicki, and Mr. Amit Munshi. They are responsible for the company's strategic direction and operations.

As of March 2022, the management team of Pulmatrix, Inc. includes the following individuals:<BR><BR>- Mr. Michael Higgins, Independent Chairman of the Board<BR>- Mr. Teofilo Raad, President, Chief Executive Officer, Director<BR>- Mr. Todd Bazemore, Director<BR>- Dr. Christopher Cabell, Director<BR>- Dr. Rick Batycky, Independent Director<BR>- Mr. Mark Iwicki, Independent Director<BR>- Mr. Amit Munshi, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Is Pulmatrix, Inc. overvalued or undervalued?

As of August 6, 2025, Pulmatrix, Inc. is considered overvalued with a valuation grade of "does not qualify," highlighted by a Price to Book Value of 4.54, negative EV to EBIT and EV to EBITDA ratios, and a Return on Equity of -170.58%, despite a strong 1-year return of 131.13% compared to the S&P 500's 17.14%.

As of 6 August 2025, the valuation grade for Pulmatrix, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. The company appears to be overvalued given its current financial metrics, including a Price to Book Value of 4.54 and negative ratios for EV to EBIT and EV to EBITDA at -2.54 and -2.59, respectively. Additionally, the Return on Equity (ROE) stands at a staggering -170.58%, further highlighting the company's struggles.<BR><BR>In comparison to its peers, Pulmatrix's valuation ratios are less favorable; for instance, Cyclerion Therapeutics, Inc. has an EV to EBITDA of -1.2082, while Sunshine Biopharma, Inc. shows a more manageable EV to EBITDA of 0.7084. The stock has had a mixed performance against the S&P 500, with a 1-year return of 131.13% compared to the index's 17.14%, but it has underperformed significantly year-to-date with a return of -29.80% against the S&P 500's 12.22%. Overall, these factors suggest that Pulmatrix, Inc. is currently overvalued.

Is Pulmatrix, Inc. technically bullish or bearish?

As of August 28, 2025, Pulmatrix, Inc. has a mildly bearish trend influenced by mixed technical indicators, underperforming the S&P 500 year-to-date with a -29.80% return, but significantly outperforming over the past year with a 131.13% return.

As of 28 August 2025, the technical trend for Pulmatrix, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven primarily by the weekly MACD and Bollinger Bands indicating bearish signals, while the monthly indicators show a mildly bullish trend. The weekly RSI is bullish, but the daily moving averages are bearish, contributing to the overall mildly bearish outlook. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 year-to-date with a return of -29.80% compared to the index's 12.22%, although it has significantly outperformed over the past year with a return of 131.13% versus the S&P 500's 17.14%.